Daiwa Securities Group
SYRS

Daiwa Securities Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Daiwa Securities Group’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10
Closed – – 1403
2022
Q3 		$0 Hold
10
– – ﹤0.01% 1412
2022
Q2 		$0 Hold
10
– – ﹤0.01% 1442
2022
Q1 		$0 Hold
10
– – ﹤0.01% 1430
2021
Q4 		$0 Hold
10
– – ﹤0.01% 1461
2021
Q3 		$0 Hold
10
– – ﹤0.01% 1348
2021
Q2 		$1K Hold
10
– – ﹤0.01% 1226
2021
Q1 		$1K Hold
10
– – ﹤0.01% 1237
2020
Q4 		$1K Sell
10
-17
-63% -$1.55K ﹤0.01% 1218
2020
Q3 		$2K Hold
27
– – ﹤0.01% 1149
2020
Q2 		$2K Hold
27
– – ﹤0.01% 1168
2020
Q1 		$2K Hold
27
– – ﹤0.01% 1170
2019
Q4 		$2K Hold
27
– – ﹤0.01% 1172
2019
Q3 		$3K Buy
27
+5
+23% +$472 ﹤0.01% 1111
2019
Q2 		$2K Hold
22
– – ﹤0.01% 1158
2019
Q1 		$2K Buy
+22
New +$1.53K ﹤0.01% 1144

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

Daiwa Securities Group's SYRS Position: Q4 2022 in Review

Daiwa Securities Group sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2022, closing a stake of 10 shares.

Daiwa Securities Group first reported a position in SYRS in Q1 2019 and held it in 15 quarters. The position peaked at $3K in Q3 2019. 57 funds tracked by Wall St. Rank hold SYRS as of Q4 2022.

  • Daiwa Securities Group reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Daiwa Securities Group sold 10 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2022.
  • Daiwa Securities Group first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 15 quarters.
  • Daiwa Securities Group's Syros Pharmaceuticals, Inc. Common Stock position peaked at $3K in Q3 2019.
  • 57 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Daiwa Securities Group's 13F filing for Q4 2022, filed 6 Feb 2023.